Yahoo Finance If You Invested $1000 in Hologic 10 Years Ago, This Is How Much You'd Have Now
How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries.
FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.
What if you'd invested in Hologic (HOLX) ten years ago? It may not have been easy to hold on to HOLX for all that time, but if you did, how much would your investment be worth today?
Hologic's Business In-Depth
With that in mind, let's take a look at Hologic's main business drivers.
Headquartered in Bedford, MA, Hologic Inc. develops, manufactures, and supplies diagnostics, medical imaging systems and surgical products which cater to the healthcare needs of women.
Hologic operates through the following four segments:
Diagnostics (55% of total revenues in FY22): With the Gen-Probe acquisition, Hologic currently offers APTIMA family of assays that includes the APTIMA Combo 2 assay, which feature the APTIMA CT and APTIMA GC assays, the APTIMA HPV assay and the APTIMA Trichomonas assay. Other products include the ThinPrep system, primarily used in cytology applications.
Breast Health (29% of total revenues in FY22): Products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, computer-aided detection (CAD), breast biopsy guidance systems, minimally invasive breast biopsy and tissue extraction devices and breast brachytherapy products.
GYN Surgical (14% of total revenues in FY22): Products include the NovaSure endometrial ablation system – used in the treatment of heavy menstrual bleeding and the MyoSure hysteroscopic tissue removal system – which allows incision less removal of fibroids and polyps within the uterus.
Skeletal Health (2% of total revenues in FY22): This segment includes dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini-C arm imaging products.
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in Hologic a decade ago, you're probably feeling pretty good about your investment today.
A $1000 investment made in February 2013 would be worth $3,413.17, or a 241.32% gain, as of February 1, 2023, according to our calculations. Investors should note that this return excludes dividends but includes price increases.
The S&P 500 rose 172.12% and the price of gold increased 11.12% over the same time frame in comparison.
Analysts are anticipating more upside for HOLX.
Hologic delivered better-than-expected revenues and earnings for the fourth quarter of fiscal 2022. Both molecular diagnostics and surgical businesses grew strong. Excluding COVID impact, molecular diagnostics business grew primarily on more assays being run through the company’s expanded Panther installed base. GYN Surgical business grew nearly 9% organically as the company registered procedural volumes return as well as acceleration from the new business lines. In the past year, Hologic has outperformed its industry. However, on a year-over-year basis, earnings and revenues were significantly down. The significant decline in COVID-19 assay revenues, along with supply chain challenges related to semiconductor chips in the Breast Health business, dragged total revenues down. The company also reported a contraction in both margins.
Shares have gained 7.70% over the past four weeks and there have been 2 higher earnings estimate revisions for fiscal 2022 compared to none lower. The consensus estimate has moved up as well.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
